|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
WO2013006486A2
(en)
|
2011-07-01 |
2013-01-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
LT3495367T
(lt)
|
2012-06-13 |
2021-02-25 |
Incyte Holdings Corporation |
Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
|
|
NZ703495A
(en)
|
2012-07-11 |
2018-02-23 |
Blueprint Medicines Corp |
Inhibitors of the fibroblast growth factor receptor
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
WO2014085365A2
(en)
|
2012-11-28 |
2014-06-05 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
IL292303A
(en)
|
2012-12-27 |
2022-06-01 |
Ngm Biopharmaceuticals Inc |
Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
JP6576325B2
(ja)
*
|
2013-03-15 |
2019-09-18 |
セルジーン シーエーアール エルエルシー |
ヘテロアリール化合物およびそれらの使用
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
|
CA2907243C
(en)
*
|
2013-03-15 |
2021-12-28 |
Celgene Avilomics Research, Inc. |
Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
|
|
US9321786B2
(en)
|
2013-03-15 |
2016-04-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
LT2986610T
(lt)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicikliniai heterociklai, kaip fgfr inhibitoriai
|
|
AU2014287209B2
(en)
*
|
2013-07-09 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
DK3035936T3
(da)
|
2013-08-23 |
2019-06-11 |
Neupharma Inc |
Visse kemiske enheder, sammensætninger og fremgangsmåder
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
LT3057969T
(lt)
|
2013-10-17 |
2018-07-10 |
Blueprint Medicines Corporation |
Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
|
|
SMT201800379T1
(it)
|
2013-10-18 |
2018-09-13 |
Eisai R&D Man Co Ltd |
Inibitori di fgfr4 della pirimidina
|
|
DK3395814T3
(da)
|
2013-10-25 |
2022-07-04 |
Blueprint Medicines Corp |
Hæmmere af fibroblastvækstfaktorreceptoren
|
|
BR112016008276B1
(pt)
|
2013-10-25 |
2021-03-02 |
Novartis Ag |
derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
|
|
SG11201602870YA
(en)
|
2013-10-28 |
2016-05-30 |
Ngm Biopharmaceuticals Inc |
Cancer models and associated methods
|
|
WO2015108992A1
(en)
*
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
|
AU2015206292B2
(en)
|
2014-01-20 |
2018-02-15 |
Cleave Biosciences, Inc. |
Fused pyrimidines as inhibitors of p97 complex
|
|
PL3097122T3
(pl)
|
2014-01-24 |
2020-10-19 |
Ngm Biopharmaceuticals, Inc. |
Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
|
|
EP3102577B1
(en)
|
2014-02-07 |
2018-07-18 |
Principia Biopharma Inc. |
Quinolone derivatives as fibroblast growth factor receptor inhibitors
|
|
US9932329B2
(en)
|
2014-03-03 |
2018-04-03 |
Principia Biopharma, Inc. |
Benzimidazole derivatives as RLK and ITK inhibitors
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN105017227B
(zh)
*
|
2014-07-08 |
2018-03-09 |
四川百利药业有限责任公司 |
N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
|
|
MX369646B
(es)
|
2014-08-18 |
2019-11-15 |
Eisai R&D Man Co Ltd |
Sal de derivado de piridina monociclico y su cristal.
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016054483A1
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016065106A1
(en)
|
2014-10-23 |
2016-04-28 |
Ngm Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
|
WO2016073855A1
(en)
|
2014-11-07 |
2016-05-12 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2016115412A1
(en)
*
|
2015-01-18 |
2016-07-21 |
Newave Pharmaceutical Llc |
Dual-warhead covalent inhibitors of fgfr-4
|
|
WO2016127074A1
(en)
|
2015-02-06 |
2016-08-11 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
|
|
EP3270694A4
(en)
*
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
MA41551A
(fr)
*
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
SG11201706287PA
(en)
|
2015-02-20 |
2017-09-28 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
CA2976766A1
(en)
|
2015-03-25 |
2016-09-29 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
|
US9802917B2
(en)
|
2015-03-25 |
2017-10-31 |
Novartis Ag |
Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
|
AU2016237222B2
(en)
|
2015-03-25 |
2021-04-29 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for bile duct cancer
|
|
MX382355B
(es)
|
2015-04-10 |
2025-03-13 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
|
|
CN107660200B
(zh)
|
2015-04-14 |
2022-01-11 |
卫材R&D管理有限公司 |
结晶fgfr4抑制剂化合物和其用途
|
|
EP3283462B1
(en)
|
2015-04-15 |
2020-12-02 |
Araxes Pharma LLC |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
US10538517B2
(en)
|
2015-05-22 |
2020-01-21 |
Principia Biopharma, Inc. |
Quinolone derivatives as FGFR inhibitors
|
|
EP3303334B1
(en)
|
2015-06-03 |
2021-06-02 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
HUE053067T2
(hu)
|
2015-07-16 |
2021-06-28 |
Array Biopharma Inc |
Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
AU2016297754A1
(en)
|
2015-07-24 |
2018-02-15 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to KIT and PDGFR
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
US10538518B2
(en)
*
|
2015-08-11 |
2020-01-21 |
Principia Biopharma, Inc. |
Processes for preparing an FGFR inhibitor
|
|
CA2995997A1
(en)
|
2015-08-26 |
2017-03-02 |
Blueprint Medicines Corporation |
Compounds and compositions useful for treating disorders related to ntrk
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3365335B1
(en)
*
|
2015-10-23 |
2024-02-14 |
Array Biopharma, Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
|
|
TN2018000138A1
(en)
|
2015-10-26 |
2019-10-04 |
Array Biopharma Inc |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
NZ742351A
(en)
|
2015-11-02 |
2023-03-31 |
Blueprint Medicines Corp |
Inhibitors of ret
|
|
AU2016353988B2
(en)
|
2015-11-09 |
2019-09-26 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
|
EP3377481A1
(en)
|
2015-11-16 |
2018-09-26 |
Araxes Pharma LLC |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
MX2018006195A
(es)
|
2015-11-19 |
2018-09-05 |
Blueprint Medicines Corp |
Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
|
|
CA3001969C
(en)
|
2015-12-17 |
2023-10-03 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for breast cancer
|
|
CN105669566A
(zh)
*
|
2016-03-09 |
2016-06-15 |
华东师范大学 |
一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法
|
|
UY37155A
(es)
|
2016-03-17 |
2017-10-31 |
Blueprint Medicines Corp |
Inhibidores de ret
|
|
AU2017246554B2
(en)
|
2016-04-04 |
2022-08-18 |
Loxo Oncology, Inc. |
Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
ES2987501T3
(es)
|
2016-04-04 |
2024-11-15 |
Loxo Oncology Inc |
Métodos de tratamiento de cánceres pediátricos
|
|
FI3442977T3
(fi)
|
2016-04-15 |
2023-09-26 |
Blueprint Medicines Corp |
Aktiviinireseptorin kaltaisen kinaasin estäjät
|
|
EP3454898B1
(en)
|
2016-05-10 |
2021-11-10 |
Eisai R&D Management Co., Ltd. |
Drug combinations for reducing cell viability and/or cell proliferation
|
|
KR102566858B1
(ko)
|
2016-05-18 |
2023-08-11 |
어레이 바이오파마 인크. |
(s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
|
|
WO2018004258A1
(ko)
*
|
2016-06-28 |
2018-01-04 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
KR20180002053A
(ko)
*
|
2016-06-28 |
2018-01-05 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018017983A1
(en)
|
2016-07-22 |
2018-01-25 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to ret
|
|
US10035789B2
(en)
|
2016-07-27 |
2018-07-31 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
EP3497087B1
(en)
|
2016-08-15 |
2021-11-10 |
Neupharma, Inc. |
Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
|
|
WO2018039557A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
EP3508482B1
(en)
*
|
2016-09-01 |
2020-12-16 |
Nanjing Transthera Biosciences Co. Ltd. |
Inhibitors of fibroblast growth factor receptor and use thereof
|
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
WO2018072707A1
(zh)
*
|
2016-10-18 |
2018-04-26 |
保诺科技（北京）有限公司 |
芳香族醚类衍生物、其制备方法及其在医药上的应用
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
US11229643B2
(en)
|
2016-11-02 |
2022-01-25 |
Novartis Ag |
Combinations of FGFR4 inhibitors and bile acid sequestrants
|
|
KR102249632B1
(ko)
*
|
2016-11-17 |
2021-05-10 |
광동 쫑성 파마세티컬 컴패니, 리미티드 |
Fgfr4 억제제, 이의 제조 방법 및 응용
|
|
KR101812266B1
(ko)
|
2016-11-25 |
2017-12-27 |
한국과학기술연구원 |
4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
|
|
US10968220B2
(en)
*
|
2016-12-19 |
2021-04-06 |
Abbisko Therapeutics Co., Ltd. |
FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
|
|
CN108239069B
(zh)
*
|
2016-12-26 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
一种用于成纤维细胞生长因子受体的抑制剂及其用途
|
|
CN108264511B
(zh)
*
|
2017-01-03 |
2021-04-13 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和其在医药上的用途
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
US11168090B2
(en)
|
2017-01-18 |
2021-11-09 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
CN108503593B
(zh)
*
|
2017-02-28 |
2021-04-27 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
US11040979B2
(en)
|
2017-03-31 |
2021-06-22 |
Blueprint Medicines Corporation |
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
CA3074885A1
(en)
*
|
2017-09-05 |
2019-03-14 |
Bioardis Llc |
Aromatic derivative, preparation method for same, and medical applications thereof
|
|
TWI812649B
(zh)
|
2017-10-10 |
2023-08-21 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
AU2018350980C1
(en)
|
2017-10-18 |
2024-12-12 |
Incyte Corporation |
Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
|
|
KR20190043437A
(ko)
|
2017-10-18 |
2019-04-26 |
씨제이헬스케어 주식회사 |
단백질 키나제 억제제로서의 헤테로고리 화합물
|
|
EP3697786B1
(en)
|
2017-10-18 |
2022-08-31 |
Blueprint Medicines Corporation |
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
|
|
WO2019085894A1
(zh)
*
|
2017-10-30 |
2019-05-09 |
如东凌达生物医药科技有限公司 |
一类含氮稠环化合物及其制备方法和用途
|
|
EP3740490A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
|
|
CA3087972C
(en)
|
2018-01-18 |
2023-01-10 |
Array Biopharma Inc. |
Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
|
|
EP3740491A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
ES2936627T3
(es)
|
2018-02-08 |
2023-03-21 |
Zhangzhou Pien Tze Huang Pharm |
Compuesto de pirazina-2(1H)-cetona como inhibidor de FGFR
|
|
JPWO2019189241A1
(ja)
|
2018-03-28 |
2021-03-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝細胞癌治療剤
|
|
EP3773589B1
(en)
|
2018-04-03 |
2023-11-01 |
Blueprint Medicines Corporation |
Ret inhibitor for use in treating cancer having a ret alteration
|
|
CN110386921A
(zh)
*
|
2018-04-23 |
2019-10-29 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂化合物
|
|
MX2020011718A
(es)
|
2018-05-04 |
2021-02-15 |
Incyte Corp |
Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
|
|
ES3061844T3
(en)
|
2018-05-04 |
2026-04-07 |
Incyte Corp |
Salts of an fgfr inhibitor
|
|
CN111868058B
(zh)
*
|
2018-05-25 |
2023-06-13 |
上海和誉生物医药科技有限公司 |
一种fgfr抑制剂、其制备方法和在药学上的应用
|
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
|
CN112313207B
(zh)
*
|
2018-06-22 |
2023-02-14 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
CA3224985C
(en)
|
2018-07-31 |
2025-11-18 |
Loxo Oncology, Inc. |
SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
JP2022500383A
(ja)
|
2018-09-10 |
2022-01-04 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
|
|
US12351576B2
(en)
|
2018-09-14 |
2025-07-08 |
Abbisko Therapeutics Co., Ltd. |
FGFR inhibitor, preparation method therefor and application thereof
|
|
CN110950867A
(zh)
*
|
2018-09-27 |
2020-04-03 |
首药控股(北京)有限公司 |
一种fgfr4激酶抑制剂及其制备方法和用途
|
|
CN111138459B
(zh)
*
|
2018-11-06 |
2022-10-18 |
南京圣和药业股份有限公司 |
Fgfr4抑制剂的光学异构体及其应用
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020119606A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of fibroblast growth factor receptor
|
|
EP3898626A1
(en)
*
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
CN113474337A
(zh)
|
2018-12-19 |
2021-10-01 |
奥瑞生物药品公司 |
作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
|
|
WO2020177067A1
(en)
|
2019-03-05 |
2020-09-10 |
Bioardis Llc |
Aromatic derivatives, preparation methods, and medical uses thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
JP7378488B2
(ja)
*
|
2019-03-08 |
2023-11-13 |
ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド |
Ｆｇｆｒ４キナーゼ阻害剤、その製造方法及び用途
|
|
ES2966512T3
(es)
|
2019-04-12 |
2024-04-22 |
Blueprint Medicines Corp |
Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración
|
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
JP7300057B2
(ja)
*
|
2019-07-26 |
2023-06-28 |
シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド |
Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としてのピリジン誘導体
|
|
JP7198388B2
(ja)
*
|
2019-08-08 |
2022-12-28 |
▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 |
ピラジン－２（１ｈ）－ケトン化合物の結晶形ａ及び結晶形ｂ及びその製造方法
|
|
WO2021023193A1
(zh)
*
|
2019-08-08 |
2021-02-11 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的制备方法
|
|
EP4011869B1
(en)
*
|
2019-08-08 |
2023-11-15 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Crystal form d of pyrazine-2(1h)-ketone compound and preparation method therefor
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN112759593A
(zh)
|
2019-11-01 |
2021-05-07 |
北京伯汇生物技术有限公司 |
桥环并醛基吡啶衍生物及其应用
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
EP4069369A4
(en)
|
2019-12-06 |
2024-02-14 |
Schrödinger, Inc. |
CYCLIC COMPOUNDS AND METHODS OF USE
|
|
CN113087671B
(zh)
*
|
2019-12-23 |
2022-10-21 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
IL294214B2
(en)
|
2019-12-27 |
2026-04-01 |
Schrodinger Inc |
Cyclic compounds and methods for using them
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CA3183728A1
(en)
|
2020-05-29 |
2021-12-02 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
US20230374015A1
(en)
*
|
2020-06-05 |
2023-11-23 |
Kinnate Biopharma Inc. |
Inhibitors of fibroblast growth factor receptor kinases
|
|
JP2023541047A
(ja)
|
2020-09-10 |
2023-09-27 |
シュレーディンガー， インコーポレイテッド |
がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
|
|
CN112851587A
(zh)
*
|
2021-01-21 |
2021-05-28 |
药雅科技(上海)有限公司 |
一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
|
|
JP2024505890A
(ja)
|
2021-01-26 |
2024-02-08 |
シュレーディンガー， インコーポレイテッド |
がん、自己免疫及び炎症性障害の治療に有用な三環式化合物
|
|
AU2022213682C1
(en)
*
|
2021-01-26 |
2025-04-17 |
Cgenetech (Suzhou, China) Co., Ltd |
Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method therefor
|
|
CN114853740B
(zh)
*
|
2021-02-03 |
2023-08-01 |
药雅科技(上海)有限公司 |
炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途
|
|
TWI820622B
(zh)
*
|
2021-03-04 |
2023-11-01 |
美商美國禮來大藥廠 |
Fgfr3抑制劑化合物
|
|
WO2022194160A1
(zh)
*
|
2021-03-16 |
2022-09-22 |
上海启晟合研医药科技有限公司 |
非索替尼固体形式及其制备方法
|
|
TW202300150A
(zh)
|
2021-03-18 |
2023-01-01 |
美商薛定諤公司 |
環狀化合物及其使用方法
|
|
CA3213379A1
(en)
*
|
2021-03-26 |
2022-09-29 |
Weiqiang Zhan |
Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation, and a use thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
CN113912602B
(zh)
*
|
2021-10-14 |
2023-05-05 |
温州医科大学 |
一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
|
|
CN121548581A
(zh)
*
|
2023-05-25 |
2026-02-17 |
魔法弹丸治疗 |
用于抑制蛋白激酶的新型化合物和包含该化合物的药物组合物
|
|
TWI896159B
(zh)
*
|
2023-06-09 |
2025-09-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
CN122003418A
(zh)
|
2023-09-11 |
2026-05-08 |
薛定谔公司 |
作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物
|